ABEO
Abeona Therapeutics Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona's clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa in Phase 3 development, as well as ABO-102 and ABO-101, novel AAV-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB), respectively, in Phase 1/2 development. The Company's portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical needs. Abeona's novel, next-generation AIM™ capsids have shown potential to improve tropism profiles for a variety of devastating diseases. Abeona's fully functional, gene and cell therapy GMP manufacturing facility produces EB-101 for the pivotal Phase 3 VIITAL™ study and is capable of clinical and commercial production of AAV-based gene therapies.
Market Cap: 123 Million
Primary Exchange: NASDAQ
Website: abeonatherapeutics.com
Shares Outstanding: 101 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.186008820120932
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 959 trading days
From: 2018-05-17 To: 2021-09-23
Lowest Point:
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2019 Update
via: SeekingAlpha at 2019-06-12 01:06:09:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens 13F stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 05/15/2019. Please visit our Tracking Ole Andreas Halvorsen… read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2019 Update
via: SeekingAlpha at 2019-06-12 01:06:09:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens 13F stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 05/15/2019. Please visit our Tracking Ole Andreas Halvorsen… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|